WO2010063662A1 - N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof - Google Patents
N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof Download PDFInfo
- Publication number
- WO2010063662A1 WO2010063662A1 PCT/EP2009/066016 EP2009066016W WO2010063662A1 WO 2010063662 A1 WO2010063662 A1 WO 2010063662A1 EP 2009066016 W EP2009066016 W EP 2009066016W WO 2010063662 A1 WO2010063662 A1 WO 2010063662A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disorder
- sleep
- pharmaceutically acceptable
- methyl
- acceptable salt
- Prior art date
Links
- SVWMQHAGDTYGQL-WPOPWMOTSA-O CC(C)(c1ccccc11)[SiH]1c1ccccc1C([C@H](CC=O)NC(OCc1ccccc1)=O)[OH2+] Chemical compound CC(C)(c1ccccc11)[SiH]1c1ccccc1C([C@H](CC=O)NC(OCc1ccccc1)=O)[OH2+] SVWMQHAGDTYGQL-WPOPWMOTSA-O 0.000 description 1
- HRHDLPNATLLLEH-UHFFFAOYSA-N Cc1ccc(C(O)=O)c(C(OC)=O)n1 Chemical compound Cc1ccc(C(O)=O)c(C(OC)=O)n1 HRHDLPNATLLLEH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Definitions
- This invention relates to ⁇ /- ⁇ [(15',45',65)-3-(2-pyridinylcarbonyl)-3- azabicyclo[4.1.0]hept-4-yl]methyl ⁇ -2-heteroarylamine derivatives and their use as pharmaceuticals.
- polypeptides and polynucleotides encoding polypeptides which are ligands for the orexin-1 receptor, e.g. orexin-A (Lig72A) are disclosed in EP849361.
- orexin receptor antagonist SB334867 potently reduced hedonic eating in rats (White et al (2005) Peptides 26 pp 2231 to 2238) and also attenuated high-fat pellet self- administration in rats (Nair et al (2008) British Journal of Pharmacology, published online 28 January 2008).
- the search for new therapies to treat obesity and other eating disorders is an important challenge.
- WHO definitions a mean of 35% of subjects in 39 studies were overweight and a further 22% clinically obese in westernised societies. It has been estimated that 5.7% of all healthcare costs in the USA are a consequence of obesity. About 85% of Type 2 diabetics are obese. Diet and exercise are of value in all diabetics.
- diabetes The incidence of diagnosed diabetes in westernised countries is typically 5% and there are estimated to be an equal number undiagnosed.
- the incidence of obesity and Type 2 diabetes is rising, demonstrating the inadequacy of current treatments which may be either ineffective or have toxicity risks including cardiovascular effects.
- Treatment of diabetes with sulfonylureas or insulin can cause hypoglycaemia, whilst metformin causes GI side- effects.
- No drug treatment for Type 2 diabetes has been shown to reduce the long-term complications of the disease. Insulin sensitisers will be useful for many diabetics, however they do not have an anti-obesity effect.
- the orexin system is also involved in sleep and wakefulness.
- Rat sleep/EEG studies have shown that central administration of orexin- A, an agonist of the orexin receptors, causes a dose-related increase in arousal, largely at the expense of a reduction in paradoxical sleep and slow wave sleep 2, when administered at the onset of the normal sleep period (Hagan et al (1999) Proc.Natl.Acad.Sci. 96 pp 10911 to 10916).
- the role of the orexin system in sleep and wakefulness is now well established (Sakurai (2007) Nature Reviews Neuroscience 8 pp 171 to 181; Ohno and Sakurai (2008) Front.
- Antagonists of the orexin receptors may therefore be useful in the treatment of sleep disorders including insomnia.
- WO00/47580 disclose phenyl urea derivatives and WO00/47576 discloses quinolinyl cinnamide derivatives as orexin receptor antagonists.
- WO05/118548 discloses substituted 1,2,3,4-tetrahydroisoquinoline derivatives as orexin antagonists.
- WO01/96302 discloses cyclic amine derivatives.
- WO08/038251 discloses 3-aza-bicyclo[3.1.0]hexane derivatives as orexin antagonists. We have now found that N- ⁇ [(15',45',65)-3-(2-pyridinylcarbonyl)-3- azabicyclo[4.1.0]hept-4-yl]methyl ⁇ -2-heteroarylamine derivatives have beneficial properties including, for example, high potency, good brain penetration and good bioavailability.
- Het is a heteroaryl group selected from the group consisting of pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl, said heteroaryl group being optionally substituted with 1 , 2 or 3 substituents independently selected from the group consisting of: C 1-4 alkyl, halo, C ⁇ alkoxy, haloC ⁇ alkyl, haloC ⁇ alkoxy and cyano; R 1 is Ci_ 4 alkyl, halo, C ⁇ alkoxy, haloCi_ 4 alkyl, haloC ⁇ alkoxy, cyano, Ci_ 4 alkylSO 2 , C 3 _ 8 cycloalkylSO2, C3_gcycloalkylCH 2 S ⁇ 2, phenyl or a 5 or 6 membered heterocyclyl group containing 1, 2 or 3 atoms selected from N, O or S, which phenyl or heterocyclyl group is optionally substituted with C 1-4 alkyl,
- Het is a heteroaryl group selected from the group consisting of pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl, said heteroaryl group being optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of: C 1-4 alkyl, halo, C ⁇ alkoxy, haloC 1 _ 4 alkyl, haloC ⁇ alkoxy and cyano; R 1 is C 1-4 alkyl, halo, C ⁇ alkoxy, haloC 1 _ 4 alkyl, haloC ⁇ alkoxy, cyano, C 1 _ 4 alkylSO 2 , C 3 _g cycloalkylSO 2 , C3_8cycloalkylCH 2 S ⁇ 2, phenyl or a 5 or 6 membered heterocyclyl group containing 1, 2 or 3 atoms selected from N, O or S, which phenyl or heterocyclyl group is optionally substituted
- R 2 is Ci_ 4 alkyl, halo, C ⁇ alkoxy, haloC ⁇ alkyl, haloC ⁇ alkoxy, cyano, phenyl or a 5 or 6 membered heterocyclyl group containing 1, 2 or 3 atoms selected from N, O or S, which phenyl or heterocyclyl group is optionally substituted with 1 or 2 groups selected from C 1 . 4 alkyl, halo, C ⁇ alkoxy, haloC ⁇ alkyl, haloC ⁇ alkoxy or cyano;
- R 3 is Ci_ 4 alkyl, halo, C ⁇ alkoxy, haloC ⁇ alkyl, haloC 1 _ 4 alkoxy or cyano; m is 0 or 1; and n is 0 or 1; or a pharmaceutically acceptable salt thereof.
- Het is substituted with haloC ⁇ alkyl.
- Het is substituted with trifluoromethyl. In one embodiment Het is pyridinyl.
- Het is pyridazinyl.
- Het is pyrazinyl
- Het is pyrimidinyl
- Het is pyridinyl substituted with trifluoromethyl or cyano. In another embodiment Het is pyrimidinyl substituted with 1 or 2 CH 3 groups.
- n and n are both 0.
- n is 0.
- R 1 is CH 3 .
- R 1 is CH 3 and m and n are both 0.
- R 2 is methoxy, ethoxy or propoxy.
- R 2 is phenyl, pyrimidinyl, oxadiazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, imidazolyl, pyrazolinyl, pyridazinyl, pyrazinyl or pyridinyl.
- R 2 is phenyl substituted with fluoro.
- R 2 is oxadiazolyl, oxazolyl or thiazolyl substituted with methyl.
- R 2 is oxadiazolyl, oxazolyl or thiazolyl substituted with ethyl.
- m is 1
- n is 0,
- R 1 is CH 3 and
- R 2 is methoxy, ethoxy or propoxy.
- Het is pyridinyl, m is 1, n is 0, R 1 is CH 3 , R 2 is methoxy, ethoxy or propoxy.
- Het is pyridinyl substituted with trifluoromethyl or cyano, m is 1 , n is 0, R 1 is CH 3 and R 2 is methoxy, ethoxy or propoxy.
- Het is pyrimidinyl
- m is 1
- n is 0,
- R 1 is CH 3 and
- R 2 is methoxy, ethoxy or propoxy.
- Het is pyrimidinyl substituted with 1 or 2 CH 3 groups, m is
- R 1 is CH 3 and R 2 is methoxy, ethoxy or propoxy.
- Het is pyridinyl substituted with haloC ⁇ alkyl; R 1 is C 1 . 4 alkyl; R 2 is ethoxy, propoxy or pyrimidinyl; m is 1 ; and n is 0.
- Het is pyridinyl substituted with trifluoromethyl; R 1 is methyl; R 2 is ethoxy, propoxy or pyrimidinyl; m is 1 ; and n is 0.
- Het is pyridinyl substituted with trifluoromethyl, m is 1 , n is 0, R 1 is CH 3 and R 2 is pyrimidinyl.
- Het is pyrazinyl substituted with trifluoromethyl, m is 1, n is 0, R 1 is CH 3 and R 2 is pyrimidinyl, or a pharmaceutically acceptable salt thereof.
- Het is pyridinyl optionally substituted with 1 , 2 or 3 substituents independently selected from the group consisting of: Ci_ 4 alkyl, halo, Ci_ 4 alkoxy, haloCi. 4 alkyl, haloC ⁇ alkoxy and cyano; R 1 is Ci_ 4 alkyl, halo, Ci_ 4 alkoxy, haloC ⁇ alkyl, ImIoC 1 .
- R 2 is Ci_ 4 alkyl, halo, Ci_ 4 alkoxy, haloC ⁇ alkyl, haloC ⁇ alkoxy, cyano, phenyl or a 5 or 6 membered heterocyclyl group containing 1, 2 or 3 atoms selected from N, O or S, which phenyl or heterocyclyl group is optionally substituted with C 1-4 alkyl, halo, C ⁇ alkoxy, haloC ⁇ alkyl, haloCi_ 4 alkoxy or cyano; m is 1; and n is 0.
- Het is pyridinyl substituted with 1 substituent selected from the group consisting of: C 1-4 alkyl, halo, C ⁇ alkoxy, haloC ⁇ alkyl, haloC ⁇ alkoxy and cyano;
- R 1 is C 1-4 alkyl, halo, C ⁇ alkoxy, haloCi_ 4 alkyl, haloCi_ 4 alkoxy, cyano;
- R 2 is C 1 . 4 alkoxy or a 5 or 6 membered heterocyclyl group containing 1 , 2 or 3 atoms selected from N, O or S, which heterocyclyl group is optionally substituted with C 1-4 alkyl, halo, C 1 . 4alkoxy, haloC ⁇ alkyl, haloC ⁇ alkoxy or cyano;
- the invention provides the compound of formula (I) selected from the group consisting of:
- the Het group (pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl) may be attached to the aminomethyl linker by means of a bond between the nitrogen atom in said linker and any carbon or suitable nitrogen atom in said pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl ring.
- the Het group is attached to the linker by means of a bond between the nitrogen atom in the linker and a carbon atom in the Het group ring.
- R 1 or R 2 is a heterocyclic group it can be any 5 or 6 membered heterocyclyl group containing 1, 2 or 3 atoms selected from N, O or S.
- heterocyclic groups include pyrimidinyl, oxadiazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, imidazolyl, pyrazolinyl, pyridazinyl, pyrazinyl, pyridinyl, furanyl, thienyl, pyrrolyl, thiadiazolyl, triazinyl and isothiazolyl.
- R 1 or R 2 is a heterocyclic group
- said group may be attached to the pyridyl ring by means of a bond between a carbon atom of said pyridyl ring and a carbon or a suitable heteroatom of the heterocyclic group.
- R 2 is a triazolyl group
- the attachment to the pyridyl ring may be by means of a bond between a carbon atom on the pyridyl ring and a) one of the two carbon atoms or b) one of the three nitrogen atoms of the triazolyl group.
- the alkyl group maybe straight chain, branched or cyclic, or combinations thereof. Examples of C ⁇ alkyl are methyl or ethyl.
- haloC ⁇ alkyl examples include trifluoromethyl (i.e. -CF 3 ).
- C ⁇ alkoxy examples include methoxy and ethoxy.
- haloC ⁇ alkoxy examples include trifluoromethoxy (i.e. - OCF 3 ).
- Halogen or "halo" when used, for example, in haloC ⁇ alkyl means fluoro, chloro, bromo or iodo.
- salts of the compounds of formula (I) should be pharmaceutically acceptable. Suitable pharmaceutically acceptable salts will be apparent to those skilled in the art. Pharmaceutically acceptable salts include those described by Berge, Bighley and Monkhouse J.Pharm.Sci (1977) 66, pp 1-19. Such pharmaceutically acceptable salts include acid addition salts formed with inorganic acids e.g. hydrochloric, hydrobromic, sulphuric, nitric or phosphoric acid and organic acids e.g.
- succinic maleic, acetic, fumaric, citric, tartaric, benzoic, p-toluenesulfonic, methanesulfonic or naphthalenesulfonic acid.
- Other salts e.g. oxalates or formates, may be used, for example in the isolation of compounds of formula (I) and represent another aspect of this invention.
- Certain of the compounds of formula (I) may form acid addition salts with one or more equivalents of the acid.
- the present invention includes within its scope all possible stoichiometric and non-stoichiometric forms.
- the compounds of formula (I) may be prepared in crystalline or non-crystalline form and, if crystalline, may optionally be solvated, eg. as the hydrate.
- This invention includes within its scope stoichiometric solvates (eg. hydrates) as well as compounds containing variable amounts of solvent (eg. water).
- pharmaceutically acceptable derivative includes any pharmaceutically acceptable ester or salt of such ester of a compound of formula (I) which, upon administration to the recipient is capable of providing (directly or indirectly) a compound of formula (I) or an active metabolite or residue thereof.
- the stereogenic centres of the compounds of formula (I) are in a cis (IS,4S,6S)- conf ⁇ guration.
- the invention also extends to any tautomeric forms or mixtures thereof.
- the subject invention also includes isotopically-labeled compounds which are identical to those recited in formula (I) but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number most commonly found in nature.
- isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine, iodine and chlorine such as 3 H, 11 C, 14 C, 18 F, 123 I or 125 I.
- Isotopically labeled compounds of the present invention for example those into which radioactive isotopes such as 3 H or 14 C have been incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, ie. H, and carbon-14, ie. 14 C, isotopes are particularly preferred for their ease of preparation and detectability. 11 C and 18 F isotopes are particularly useful in PET (positron emission tomography).
- the compounds of formula (I) are intended for use in pharmaceutical compositions it will readily be understood that they are each preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds maybe used for preparing the more pure forms used in the pharmaceutical compositions. According to a further aspect of the present invention there is provided a process for the preparation of compounds of formula (I) and derivatives thereof.
- the following schemes detail some synthetic routes to compounds of the invention. In the following schemes reactive groups can be protected with protecting groups and deprotected according to well established techniques.
- R 1 , R 2 , R 3 , m and n have the meanings given in formula (I). It will be understood by those skilled in the art that certain compounds of the invention can be converted into other compounds of the invention according to standard chemical methods.
- the starting materials for use in the scheme are commercially available, known in the literature or can be prepared by known methods.
- the present invention provides compounds of formula (I) or a pharmaceutically acceptable salt thereof for use in human or veterinary medicine.
- the compounds of formula (I) or their pharmaceutically acceptable salts may be of use for the treatment or prophylaxis of a disease or disorder where an antagonist of a human orexin receptor is required.
- Coumpounds of formula (I) or their pharmaceutically acceptable salts may be of use for the treatment or prophylaxis of sleep disorders selected from the group consisting of Dyssomnias such as Primary Insomnia (307.42), Primary Hypersomnia (307.44), Narcolepsy (347), Breathing-Related Sleep Disorders (780.59), Circadian Rhythm Sleep Disorder (307.45) and Dyssomnia Not Otherwise Specified (307.47); primary sleep disorders such as Parasomnias such as Nightmare Disorder (307.47), Sleep Terror Disorder (307.46), Sleepwalking Disorder (307.46) and Parasomnia Not Otherwise Specified (307.47); Sleep Disorders Related to Another Mental Disorder such as Insomnia Related to Another Mental Disorder (307.42) and Hypersomnia Related to Another Mental Disorder (307.44); Sleep Disorder Due to a General Medical Condition, in particular sleep disturbances associated with such diseases as neurological disorders, neuropathic pain, restless leg syndrome, heart and lung diseases; and Substance-Induced Sleep Disorder including the subtypes In
- compounds of formula (I) or their pharmaceutically acceptable salts maybe of use for the treatment or prophylaxis of Primary Insomnia (307.42), Circadian Rhythm Sleep Disorder (307.45) and Dyssomnia Not Otherwise Specified (307.47), Sleep Disorders Related to Another Mental Disorder such as Insomnia Related to Another Mental Disorder (307.42) and Sleep Disorder Due to a General Medical Condition, in particular sleep disturbances associated with such diseases as neurological disorders, neuropathic pain, restless leg syndrome, heart and lung diseases; and Substance-Induced Sleep Disorder including the subtypes Insomnia Type, Hypersomnia Type, Parasomnia Type and Mixed Type.
- the compounds of formula (I) or their pharmaceutically acceptable salts may be of use for the treatment or prophylaxis of depression and mood disorders including Major Depressive Episode, Manic Episode, Mixed Episode and Hypomanic Episode; Depressive Disorders including Major Depressive Disorder, Dysthymic Disorder (300.4), Depressive Disorder Not Otherwise Specified (311); Bipolar Disorders including Bipolar I Disorder, Bipolar II Disorder (Recurrent Major Depressive Episodes with Hypomanic Episodes) (296.89), Cyclothymic Disorder (301.13) and Bipolar Disorder Not Otherwise Specified (296.80); Other Mood Disorders including Mood Disorder Due to a General Medical Condition (293.83) which includes the subtypes With Depressive Features, With Major Depressive-like Episode, With Manic Features and With Mixed Features), Substance-Induced Mood Disorder (including the subtypes With Depressive Features, With Manic Features and With Mixed Features) and Mood Disorder Not Otherwise Specified (296.90).
- the compounds of formula (I) or their pharmaceutically acceptable salts may be of use for the treatment or prophylaxis of anxiety disorders including Panic Attack; Panic Disorder including Panic Disorder without Agoraphobia (300.01) and Panic Disorder with Agoraphobia (300.21); Agoraphobia; Agoraphobia Without History of Panic Disorder (300.22), Specific Phobia (300.29, formerly Simple Phobia) including the subtypes Animal Type, Natural Environment Type, Blood-Injection-Injury Type, Situational Type and Other Type), Social Phobia (Social Anxiety Disorder, 300.23), Obsessive-Compulsive Disorder (300.3), Posttraumatic Stress Disorder (309.81), Acute Stress Disorder (308.3), Generalized Anxiety Disorder (300.02), Anxiety Disorder Due to a General Medical Condition (293.84), Substance-Induced Anxiety Disorder, Separation Anxiety Disorder (309.21), Adjustment Disorders with Anxiety (309.24) and Anxiety Disorder Not Otherwise Specified (300.00).
- Panic Attack Panic
- the compounds of formula (I) or their pharmaceutically acceptable salts may be of use for the treatment or prophylaxis of substance-related disorders including Substance Use Disorders such as Substance Dependence, Substance Craving and Substance Abuse; Substance-Induced Disorders such as Substance Intoxication, Substance Withdrawal, Substance-Induced Delirium, Substance-Induced Persisting Dementia,
- Substance-Induced Persisting Amnestic Disorder, Substance-Induced Psychotic Disorder, Substance-Induced Mood Disorder, Substance-Induced Anxiety Disorder, Substance- Induced Sexual Dysfunction, Substance-Induced Sleep Disorder and Hallucinogen Persisting Perception Disorder Flashbacks
- Alcohol-Related Disorders such as Alcohol Dependence (303.90), Alcohol Abuse (305.00), Alcohol Intoxication (303.00), Alcohol Withdrawal (291.81), Alcohol Intoxication Delirium, Alcohol Withdrawal Delirium, Alcohol-Induced Persisting Dementia, Alcohol-Induced Persisting Amnestic Disorder, Alcohol-Induced Psychotic Disorder, Alcohol-Induced Mood Disorder, Alcohol-Induced Anxiety Disorder, Alcohol-Induced Sexual Dysfunction, Alcohol-Induced Sleep Disorder and Alcohol-Related Disorder Not Otherwise Specified (291.9); Amphetamine (or Amphetamine-Like)-Related Disorders such as A
- Hypnotic, or Anxiolytic Abuse (305.40), Sedative, Hypnotic, or Anxiolytic Intoxication (292.89), Sedative, Hypnotic, or Anxiolytic Withdrawal (292.0), Sedative, Hypnotic, or Anxiolytic Intoxication Delirium, Sedative, Hypnotic, or Anxiolytic Withdrawal Delirium, Sedative-, Hypnotic-, or Anxiolytic-Persisting Dementia, Sedative-, Hypnotic-, or Anxiolytic- Persisting Amnestic Disorder, Sedative-, Hypnotic-, or Anxiolytic-Induced
- the compounds of formula (I) or their pharmaceutically acceptable salts may be of use for the treatment or prophylaxis of feeding disorders such as bulimia nervosa, binge eating, obesity, including obesity observed in Type 2 (non-insulin-dependent) diabetes patients.
- the compounds of formula (I) or their pharmaceutically acceptable salts may be of use for the treatment or prophylaxis of stroke, particularly ischemic or haemorrhagic stroke and/or in blocking an emetic response i.e. nausea and vomiting.
- the invention also provides a method for the treatment of a disease or disorder in a subject, for example those diseases and disorders mentioned hereinabove, comprising administering to said subject an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.
- the invention also provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of a disease or disorder, for example those diseases and disorders mentioned hereinabove.
- the invention also provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment or prophylaxis of a disease or disorder, for example those diseases and disorders mentioned hereinabove.
- the compounds of the invention are usually administered as a pharmaceutical composition.
- the invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- the compounds of formula (I) or their pharmaceutically acceptable salts may be administered by any convenient method, e.g. by oral, parenteral, buccal, sublingual, nasal, rectal or transdermal administration, and the pharmaceutical compositions adapted accordingly.
- the compounds of formula (I) or their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids or solids, e.g. as syrups, suspensions, emulsions, tablets, capsules or lozenges.
- a liquid formulation will generally consist of a suspension or solution of the active ingredient in a suitable liquid carrier(s) e.g. an aqueous solvent such as water, ethanol or glycerine, or a non-aqueous solvent, such as polyethylene glycol or an oil.
- a suitable liquid carrier(s) e.g. an aqueous solvent such as water, ethanol or glycerine, or a non-aqueous solvent, such as polyethylene glycol or an oil.
- the formulation may also contain a suspending agent, preservative, flavouring and/or colouring agent.
- a composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations, such as magnesium stearate, starch, lactose, sucrose and cellulose.
- a composition in the form of a capsule can be prepared using routine encapsulation procedures, e.g. pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), e.g. aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
- Typical parenteral compositions consist of a solution or suspension of the active ingredient in a sterile aqueous carrier or parenterally acceptable oil, e.g. polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
- a sterile aqueous carrier or parenterally acceptable oil e.g. polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil.
- the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.
- compositions for nasal administration may conveniently be formulated as aerosols, drops, gels and powders.
- Aerosol formulations typically comprise a solution or fine suspension of the active ingredient in a pharmaceutically acceptable aqueous or non- aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container which can take the form of a cartridge or refill for use with an atomising device.
- the sealed container may be a disposable dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve.
- the dosage form comprises an aerosol dispenser, it will contain a propellant which can be a compressed gas e.g. air, or an organic propellant such as a fluorochlorohydrocarbon or hydrofluorocarbon. Aerosol dosage forms can also take the form of pump-atomisers.
- compositions suitable for buccal or sublingual administration include tablets, lozenges and pastilles where the active ingredient is formulated with a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin.
- Compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base such as cocoa butter.
- compositions suitable for transdermal administration include ointments, gels and patches.
- the composition is in unit dose form such as a tablet, capsule or ampoule.
- the composition may contain from 0.1 % to 100% by weight, for example from 10 to 60% by weight, of the active material, depending on the method of administration.
- the composition may contain from 0% to 99% by weight, for example 40% to 90% by weight, of the carrier, depending on the method of administration.
- the composition may contain from 0.05mg to lOOOmg, for example from 1.Omg to 500mg, of the active material, depending on the method of administration.
- the composition may contain from 50 mg to 1000 mg, for example from lOOmg to 400mg of the carrier, depending on the method of administration.
- the dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors.
- suitable unit doses may be 0.05 to 1000 mg, more suitably 1.0 to 500 mg, and such unit doses maybe administered more than once a day, for example two or three a day. Such therapy may extend for a number of weeks or months.
- Orexin-A (Sakurai, T. et al (1998) Cell, 92 pp 573-585) can be employed in screening procedures for compounds which inhibit the ligand's activation of the orexin-1 or orexin-2 receptors.
- screening procedures involve providing appropriate cells which express the orexin-1 or orexin-2 receptor on their surface.
- Such cells include cells from mammals, yeast, Drosophila or E. coli.
- a polynucleotide encoding the orexin- 1 or orexin-2 receptor is used to transfect cells to express the receptor.
- the expressed receptor is then contacted with a test compound and an orexin-1 or orexin-2 receptor ligand, as appropriate, to observe inhibition of a functional response.
- One such screening procedure involves the use of melanophores which are transfected to express the orexin-1 or orexin-2 receptor, as described in WO 92/01810.
- Another screening procedure involves introducing RNA encoding the orexin-1 or orexin-2 receptor into Xenopus oocytes to transiently express the receptor.
- the receptor oocytes are then contacted with a receptor ligand and a test compound, followed by detection of inhibition of a signal in the case of screening for compounds which are thought to inhibit activation of the receptor by the ligand.
- Another method involves screening for compounds which inhibit activation of the receptor by determining inhibition of binding of a labelled orexin-1 or orexin-2 receptor ligand to cells which have the orexin-1 or orexin-2 receptor (as appropriate) on their surface.
- This method involves transfecting a eukaryotic cell with DNA encoding the orexin-1 or orexin-2 receptor such that the cell expresses the receptor on its surface and contacting the cell or cell membrane preparation with a compound in the presence of a labelled form of an orexin-1 or orexin-2 receptor ligand.
- the ligand may contain a radioactive label. The amount of labelled ligand bound to the receptors is measured, e.g. by measuring radioactivity.
- Yet another screening technique involves the use of FLIPR equipment for high throughput screening of test compounds that inhibit mobilisation of intracellular calcium ions, or other ions, by affecting the interaction of an orexin-1 or orexin-2 receptor ligand with the orexin-1 or orexin-2 receptor as appropriate.
- the word 'comprise', and variations such as 'comprises' and 'comprising' will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not to the exclusion of any other integer or step or group of integers or steps.
- the compounds described in the Examples described hereinafter have all been prepared as a first step from stereochemically pure starting materials.
- the stereochemistry of the compounds of the Descriptions and Examples have been assigned on the assumption that the absolute configuration of these centres are retained.
- the relative stereochemistry of the compounds of the Descriptions and Examples have been assigned on the assumption that the relative stereochemistry is maintained as determined by using Rotating frame 2D ROESY experiments in the chiral intermediates phenylmethyl (lS,4S,6S)-4-( ⁇ [(l,l- dimethylethyl)(diphenyl)silyl]oxy ⁇ methyl)-3-azabicyclo[4.1.0]heptane-3-carboxylate (D8) and 1 , 1 -dimethylethyl (1 S,4S,6S)-4-(hydroxymethyl)-3-azabicyclo[4.1.0]heptane-3- carboxylate (D27).
- the relative stereochemistry has been confirmed on the final compounds as well.
- NMR Nuclear Magnetic Resonance
- Column T 40 0 C.
- Flow rate 1 mL/min.
- UV detection wavelength 220 nm].
- MS refers to Mass Spectra taken by Direct infusion Mass or to Mass Spectra associated with peaks taken by UPLC/MS or HPLC/MS analysis, where the Mass Spectrometer used is as mentioned below.
- MS Direct infusion Mass spectra
- MS were run on a Agilent MSD 1100 Mass Spectrometer, operating in ES (+) and ES (-) ionization mode
- ES (+) Mass range: 100-1000 amu.
- Infusion solvent water + 0.1% HCO 2 H / CH 3 CN 50/50.
- ES (-) Mass range: 100-1000 amu.
- Infusion solvent water + 0.05% NH 4 OH / CH 3 CN 50/50]
- UV and MS spectra associated with the peaks were taken on HPLC instrument Agilent
- UV detection range 210-350 nm.
- the usage of this methodology is indicated by "UPLC (Acid IPQC)" in the analytic characterization of the described compounds.
- Mobile phase A - water + 0.1% HCO 2 H / B - CH 3 CN + 0.06% or 0.1% HCO 2 H.
- UV spectra associated with the peaks were taken on a UPLC/MS AcquityTM system equipped with PDA detector and coupled to a Waters SQD mass spectrometer operating in positive and negative alternate electrospray ionisation mode
- LC/MS - ES(+ or -) analyses performed using an AcquityTM UPLC BEH C 18 column (50 x 2.1 mm, 1.7 ⁇ m particle size) column temperature 40 0 C.
- Mobile phase A - IO mM aqueous solution OfNH 4 HCO 3
- UV detection range 220-350 nm.
- the usage of this methodology is indicated by
- (+) analyses performed using a Gemini C18 AXIA column (50 x 21 mm, 5 ⁇ m particle size).
- Mobile phase A - NH 4 HCO 3 sol. 10 mM, pH 10; B - CH 3 CN. Flow rate: 17 mL/min.
- Lynx in the analytic characterization of the described compounds.
- Biotage silica cartridges e.g. Biotage SNAP cartridge
- KP-NH prepacked flash cartridges e.g., KP-NH prepacked flash cartridges
- ISCO RediSep Silica cartridges e.g. Biotage SNAP cartridge
- SPE-SCX cartridges are ion exchange solid phase extraction columns supplied by
- the eluent used with SPE-SCX cartridges is DCM and MeOH or only MeOH followed by 2 N ammonia solution in MeOH.
- the collected fractions are those eluted with the ammonia solution in MeOH.
- SPE-Si cartridges are silica solid phase extraction columns supplied by Varian.
- Ph Phenyl pH 5 buffer Acetic acid/KOAc 1 M in water solution rt retention time
- diethylzinc IM in hexane (65.5 ml, 65.5 mmol) and DCM (82 ml) were added and the resulting solution cooled at 0 0 C.
- TFA 5.05 ml, 65.5 mmol
- diiodomethane 5.29 ml, 65.5 mmol
- Description 14 [6-Methyl-3-(propyloxy)-2-pyridinyl] methanol was prepared using a similar procedure to that described above for Description 13.
- the compound of description 14 was obtained by 0-alkylation of 2-(hydroxymethyl)-6-methyl-3-pyridinol and a suitable electrophile. This is provided merely for assistance to the skilled chemist.
- the starting material may not necessarily have been prepared from the batch referred to.
- TEMPO (0.22 g, 1.40 mmol) was added and the mixture was heated to 35 0 C.
- NaClO 2 (4.51 g, 49.90 mmol) in water (10 ml) and NaClO (13 wt% aqueous solution, 18.96 ml, 39.90 mmol) were added simultaneously over 1 hour.
- the mixture was poured into an ice-cooled aqueous saturated sodium thiosulfate solution (100 ml) and stirred for a further 30 minutes.
- 2,2,6,6-tetramethylpiperidine (3.49 ml, 20.52 mmol) was dissolved in dry THF (25ml) under argon and stirred at -30 0 C; BuLi (13.33 ml, 21.33 mmol) 1.6 M in hexane was added over 5 min (the temperature never exceeded -25 0 C). The yellow solution was stirred at -30 0 C for 20 min, then chilled at -78 0 C and tris(l-methylethyl) borate (4.38 ml, 18.96 mmol) was added over 5 min (the temperature never exceeded -73 0 C).
- the vial was then capped and stirred at 65 0 C, after 1 hour the solvent was removed at reduced pressure and the residue partitioned between AcOEt (10 mis) and NaHCO 3 (saturated solution, 10 ml). The phases were separated and the water was extracted with AcOEt (2 x 10 mis). The organic fraction were joined together, dried over Na 2 SO 4 and evaporated at reduced pressure, obtaining an orange oily residue which was purified (Biotage, Snap 25 g silica gel column, AcOEt/Cy from pure Cy to 50:50 in 10 column volumes) to obtain the title compound Dl 8 as pale yellow solid (27.6 mg).
- the reaction mixture was cooled to 0 0 C and was quenched by adding in sequence: 60.7 ml of water (1 ml H 2 O x 1 g of LiAlH 4 ) + 60.7 ml of NaOH 1 N (1 ml NaOH IM x 1 g of LiAlH 4 ) + 182 ml of water (3 ml H 2 O x 1 g of LiAlH 4 ).
- the suspension was stirred at room temperature for 1 hour then the precipitate was filtered over sodium sulphate (gooch n3) and washed with Et 2 O (6 L) and DCM (4 L).
- the solvent was evaporated (temperature bath 30 0 C) of the crude title compound D20 (110 g) as pale-orange oil.
- 6-methyl-2-[(methyloxy)carbonyl]-3-pyridinecarboxylic acid D33 (1.15 g) was suspended in toluene (40 ml) and DIPEA (1.25 ml, 7.16 mmol) was added, causing the complete dissolution of the solid. This mixture was stirred 10 minutes at room temperature, then diphenyl azidophosphate (1.35 ml, 6.26 mmol) was added in one portion and the mixture was stirred at reflux for 1 hour. The solution was cooled at room temperature and t-BuOH (2.5 ml, 26 mmol) was added in one portion.
- Methyl 3 -( ⁇ [( 1 , 1 -dimethylethyl)oxy]carbonyl ⁇ amino)-6-methyl-2-pyridinecarboxylate D34 (1.3 g) was dissolved in DCM (80 ml) and the mixture stirred at 0 0 C. A solution of TFA (5 ml, 64.9 mmol) in DCM (10 ml) was dropped into the cold mixture over 3 minutes. The resulting solution was left under stirring at 0 0 C for 30 minutes, then the mixture was left still at room temperature overnight. TFA (4 ml, 51.9 mmol) dissolved in DCM (10 ml) was added over 3 minutes and the mixture stirred again at room temperature for 5 hours.
- the reaction mixture was evaporated to dryness under reduced pressure.
- the resulting mixture was evaporated to dryness under reduced pressure then the residue was triturated with DCM/MeOH (3 : 1 , 20 ml).
- the mixture was filtered washing with more DCM/MeOH (3:1, 5 ml).
- the filtrate was treated with TMS-diazomethane solution (2 M in hexanes, 2 ml, 4 mmol) to re-esterify the acid.
- the mixture was irradiated in a single mode microwave reactor to 120 0 C for a further 40 minutes.
- the reaction mixture was cooled and filtered washing the solids with EtOAc.
- the aqueous phase was extracted repeatedly with DCM; the combined DCM extracts were diluted with MeOH (50 ml) and treated with TMS-diazomethane.
- the relative stereochemistry of the compounds is derived from the stereochemistry of the previous intermediates from which the compounds were synthesised. In some Examples the relative stereochemistry has been confirmed on the final compounds as well.
- the final compounds are present as a mixture of conformers of variable ratio according to the specific Example.
- Example El is assigned the SYN relative stereochemistry derived from the stereochemistry of the previous intermediate D8.
- the product is present as a mixture of conformers.
- 6-methyl-3-(lH-pyrazol-l-yl)-2-pyridinecarboxylic acid D38 (24.63 mg) was dissolved in 1 ml of DMF, then TBTU (46.0 mg, 0.143 mmol) and DIPEA (0.025 ml, 0.143 mmol) were added. The suspension was stirred for 30 minutes at room temperature. N-[(lS,4S,6S)-3- azabicyclo[4.1.0]hept-4-ylmethyl]-5-(trifluoromethyl)-2-pyrazinamine D31 (30 mg) dissolved in 1 ml of DMF was added and the reaction was stirred overnight at room temperature. NaHCO 3 saturated solution were added, and the aqueous layer was extracted with of DCM.
- 6-methyl-3-(2H-l,2,3-triazol-2-yl)-2-pyridinecarboxylic acid D40 (33.0 mg) was dissolved in 1 ml of DCM, then TBTU (61.3 mg, 0.191 mmol) and DIPEA (0.033 ml, 0.191 mmol) were added. The suspension was stirred for 30 minutes at room temperature. N-[(1S,4S,6S)- 3-azabicyclo[4.1.0]hept-4-ylmethyl]-5-(trifluoromethyl)-2-pyrazinamine D31 (40 mg) dissolved in 1 ml of DCM was added and the reaction was stirred overnight at room temperature.
- Example 7 Determination of antagonist affinity at human Orexin-1 and 2 receptors using FLIPR
- Adherent Chinese Hamster Ovary (CHO) cells stably expressing the recombinant human Orexin-1 or human Orexin-2 receptors or Rat Basophilic Leukaemia Cells (RBL) stably expressing recombinant rat Orexin-1 or rat Orexin-2 receptors were maintained in culture in Alpha Minimum Essential Medium (Gibco/Invitrogen, cat. no.; 22571-020), supplemented with 10% decomplemented foetal bovine serum (Life Technologies, cat. no. 10106-078) and 400 ⁇ g/mL Geneticin G418 (Calbiochem, cat. no.345810). Cells were grown as monolayers under 95%:5% air:CO 2 at 37 0 C.
- the sequences of the human orexin 1, human orexin 2, rat orexin 1 and rat orexin 2 receptors used to test the compounds of examples 1 and 2 were as published in Sakurai, T. et al (1998) Cell, 92 pp 573 to 585, with the exception that the human orexin 1 receptor sequence used had the amino acid residue alanine at position 280 and not glycine as reported in Sakurai et al.
- the sequences of the receptors used to test the compounds of examples 3 to 6 were the same as above with the exception that the orexin 1 receptor sequence was identical to that published in Sakurai supra.
- the plates were then incubated at 37 0 C for 60 minutes in the dark with 2 ⁇ M FLUO-4AM dye to allow cell uptake of the FLUO-4AM, which is subsequently converted by intracellular esterases to FLUO-4, which is unable to leave the cells. After incubation, cells were washed three times with standard buffer to remove extracellular dye and 30 ⁇ L of buffer were left in each well after washing.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2009324238A AU2009324238A1 (en) | 2008-12-02 | 2009-11-30 | N-{[(IR,4S,6R-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof |
CN2009801559246A CN102300858A (en) | 2008-12-02 | 2009-11-30 | N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] Hept-4-yl] Methyl}-2-heteroarylamine Derivatives And Uses Thereof |
BRPI0922353A BRPI0922353A2 (en) | 2008-12-02 | 2009-11-30 | N DERIVATIVES - {[(1R, 4S, 6R-3- (2-PYRIDINYL CARBONYL) - 3AZABYCLE [4.1.0] HEPT-4-IL] METHIL} -2-HETEROARYLAMINE AND USES OF THE SAME |
CA2745420A CA2745420A1 (en) | 2008-12-02 | 2009-11-30 | N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof |
JP2011538975A JP2012510493A (en) | 2008-12-02 | 2009-11-30 | N-{[(IR, 4S, 6R) -3- (2-pyridinylcarbonyl) -3-azabicyclo [4.1.0] hept-4-yl] methyl} -2-heteroarylamine derivatives and their use |
EA201170741A EA201170741A1 (en) | 2008-12-02 | 2009-11-30 | DERIVATIVES N - {[(1R, 4S, 6R) -3- (2-PYRIDINILKARBONIL) -3-AZABICYCLO [4.1.0] HEPT-4-IL] METHYL} -2-HETEROARYLAMINE AND THEIR USE |
EP09760530A EP2370427A1 (en) | 2008-12-02 | 2009-11-30 | N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl]methyl}-2-heteroarylamine derivatives and uses thereof |
MX2011005799A MX2011005799A (en) | 2008-12-02 | 2009-11-30 | N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof. |
ZA2011/03482A ZA201103482B (en) | 2008-12-02 | 2011-05-12 | N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-heteroarylamine derivatives and uses thereof |
IL212925A IL212925A0 (en) | 2008-12-02 | 2011-05-16 | N-{[(ir,4s,6r-3- (2-pyridinylcarbonyl) -3-azabicyclo[4.1.0]hept -4-yl] methyl} -2- heteroarylamine derivatives and uses therreof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11911808P | 2008-12-02 | 2008-12-02 | |
US61/119,118 | 2008-12-02 | ||
US23630209P | 2009-08-24 | 2009-08-24 | |
US61/236,302 | 2009-08-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010063662A1 true WO2010063662A1 (en) | 2010-06-10 |
Family
ID=41531731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2009/066016 WO2010063662A1 (en) | 2008-12-02 | 2009-11-30 | N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof |
Country Status (16)
Country | Link |
---|---|
US (1) | US8133908B2 (en) |
EP (1) | EP2370427A1 (en) |
JP (1) | JP2012510493A (en) |
KR (1) | KR20110091581A (en) |
CN (1) | CN102300858A (en) |
AR (1) | AR074426A1 (en) |
AU (1) | AU2009324238A1 (en) |
BR (1) | BRPI0922353A2 (en) |
CA (1) | CA2745420A1 (en) |
EA (1) | EA201170741A1 (en) |
IL (1) | IL212925A0 (en) |
MX (1) | MX2011005799A (en) |
TW (1) | TW201031407A (en) |
UY (1) | UY32276A (en) |
WO (1) | WO2010063662A1 (en) |
ZA (1) | ZA201103482B (en) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011023585A1 (en) * | 2009-08-24 | 2011-03-03 | Glaxo Group Limited | Piperidine derivatives used as orexin antagonists |
WO2011050202A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
WO2011050200A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
WO2011050198A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Disubstituted octahy - dropyrrolo [3,4-c] pyrroles as orexin receptor modulators |
WO2012085852A1 (en) | 2010-12-22 | 2012-06-28 | Actelion Pharmaceuticals Ltd | 3,8-diaza-bicyclo[4.2.0]oct-8-yl amides |
WO2012089607A1 (en) * | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors |
WO2012089606A1 (en) * | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists |
WO2012145581A1 (en) | 2011-04-20 | 2012-10-26 | Janssen Pharmaceutica Nv | Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators |
WO2013050938A1 (en) | 2011-10-04 | 2013-04-11 | Actelion Pharmaceuticals Ltd | 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives |
WO2013068935A1 (en) | 2011-11-08 | 2013-05-16 | Actelion Pharmaceuticals Ltd | 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists |
ITMI20120424A1 (en) * | 2012-03-19 | 2013-09-20 | Rottapharm Spa | CHEMICAL COMPOUNDS |
WO2013182972A1 (en) | 2012-06-04 | 2013-12-12 | Actelion Pharmaceuticals Ltd | Benzimidazole-proline derivatives |
WO2014057435A1 (en) | 2012-10-10 | 2014-04-17 | Actelion Pharmaceuticals Ltd | Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives |
WO2014141065A1 (en) | 2013-03-12 | 2014-09-18 | Actelion Pharmaceuticals Ltd | Azetidine amide derivatives as orexin receptor antagonists |
WO2015083094A1 (en) | 2013-12-04 | 2015-06-11 | Actelion Pharmaceuticals Ltd | Use of benzimidazole-proline derivatives |
WO2015083070A1 (en) | 2013-12-03 | 2015-06-11 | Actelion Pharmaceuticals Ltd | Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists |
WO2015083071A1 (en) | 2013-12-03 | 2015-06-11 | Actelion Pharmaceuticals Ltd | Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1 h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
US9416109B2 (en) | 2012-02-17 | 2016-08-16 | Eisai R&D Management Co., Ltd. | Methods and compounds useful in the synthesis of orexin-2 receptor antagonists |
US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
US9499517B2 (en) | 2012-02-07 | 2016-11-22 | Eolas Therapeutics, Inc. | Substituted prolines / piperidines as orexin receptor antagonists |
WO2018146466A1 (en) | 2017-02-09 | 2018-08-16 | Benevolentai Bio Limited | Orexin receptor antagonists |
WO2018206959A1 (en) | 2017-05-10 | 2018-11-15 | Benevolentai Bio Limited | Orexin receptor antagonists |
WO2018206956A1 (en) | 2017-05-10 | 2018-11-15 | Benevolentai Bio Limited | Orexin receptor antagonists |
US10221170B2 (en) | 2014-08-13 | 2019-03-05 | Eolas Therapeutics, Inc. | Difluoropyrrolidines as orexin receptor modulators |
WO2020007964A1 (en) | 2018-07-05 | 2020-01-09 | Idorsia Pharmaceuticals Ltd | 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives |
WO2020099511A1 (en) | 2018-11-14 | 2020-05-22 | Idorsia Pharmaceuticals Ltd | Benzimidazole-2-methyl-morpholine derivatives |
US10828302B2 (en) | 2016-03-10 | 2020-11-10 | Janssen Pharmaceutica Nv | Methods of treating depression using orexin-2 receptor antagonists |
US10894789B2 (en) | 2016-02-12 | 2021-01-19 | Astrazeneca Ab | Halo-substituted piperidines as orexin receptor modulators |
WO2023218023A1 (en) | 2022-05-13 | 2023-11-16 | Idorsia Pharmaceuticals Ltd | Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201170742A1 (en) * | 2008-12-02 | 2012-01-30 | Глэксо Груп Лимитед | DERIVATIVES N - {[(1R, 4S, 6R) -3- (2-PYRIDINILCARBONYL) -3-AZABICYCLO [4.1.0] HEPT-4-IL] METHYL} -2-HETEROARYLAMINES AND THEIR APPLICATIONS |
WO2019025275A1 (en) * | 2017-07-31 | 2019-02-07 | Boehringer Ingelheim International Gmbh | Novel n-[(pyrimidinylamino)propanyl]-, n-[(pyridylamino)propanyl] - and n-[(pyrazinylamino)propanyl]arylcarboxamides |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002090355A1 (en) * | 2001-05-05 | 2002-11-14 | Smithkline Beecham P.L.C. | N-aroyl cyclic amines |
WO2004026866A1 (en) * | 2002-09-18 | 2004-04-01 | Glaxo Group Limited | N-aroyl cyclic amines as orexin receptor antagonists |
WO2004041816A1 (en) * | 2002-11-06 | 2004-05-21 | Glaxo Group Limited | Azacyclic compounds as orexin receptor antagonist |
WO2008038251A2 (en) * | 2006-09-29 | 2008-04-03 | Actelion Pharmaceuticals Ltd | 3-aza-bicyclo[3.1.0]hexane derivatives |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR016817A1 (en) | 1997-08-14 | 2001-08-01 | Smithkline Beecham Plc | DERIVATIVES OF FENILUREA OR FENILTIOUREA, PROCEDURE FOR PREPARATION, COLLECTION OF COMPOUNDS, INTERMEDIARY COMPOUNDS, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT AND USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
US6372757B1 (en) | 1998-05-08 | 2002-04-16 | Smithkline Beecham P.L.C. | Phenylurea and phenylthio urea derivatives |
WO2000047576A1 (en) | 1999-02-12 | 2000-08-17 | Smithkline Beecham Plc | Cinnamide derivatives as orexin-1 receptors antagonists |
ES2226785T3 (en) | 1999-02-12 | 2005-04-01 | Smithkline Beecham Plc | DERIVATIVES OF FENILUREA AS ANTAGONISTS OF THE RECEIVERS OF OREXINA. |
ATE282614T1 (en) | 1999-02-12 | 2004-12-15 | Smithkline Beecham Plc | PHENYL UREA AND PHENYLTHIOUREA DERIVATIVES |
ES2238458T3 (en) | 2000-06-16 | 2005-09-01 | Smithkline Beecham Plc | PIPERIDINS FOR USE AS ANTAGONISTS OF OREXIN RECEPTORS. |
ES2234929T3 (en) | 2000-11-28 | 2005-07-01 | Smithkline Beecham Plc | MORFOLINE DERIVATIVES AS ANTAGONISTS OF OREXINE RECEPTORS. |
AU2002341123A1 (en) | 2001-05-05 | 2002-11-18 | Smithkline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
WO2003002561A1 (en) | 2001-06-28 | 2003-01-09 | Smithkline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
GB0124463D0 (en) | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
GB0126292D0 (en) | 2001-11-01 | 2002-01-02 | Smithkline Beecham Plc | Compounds |
GB0127145D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Compounds |
SI1751111T1 (en) | 2004-03-01 | 2015-04-30 | Actelion Pharmaceuticals Ltd. | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives |
EP2176258A1 (en) | 2007-07-03 | 2010-04-21 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
GB0712888D0 (en) | 2007-07-03 | 2007-08-15 | Glaxo Group Ltd | Novel compounds |
GB0806536D0 (en) | 2008-04-10 | 2008-05-14 | Glaxo Group Ltd | Novel compounds |
EA201170742A1 (en) | 2008-12-02 | 2012-01-30 | Глэксо Груп Лимитед | DERIVATIVES N - {[(1R, 4S, 6R) -3- (2-PYRIDINILCARBONYL) -3-AZABICYCLO [4.1.0] HEPT-4-IL] METHYL} -2-HETEROARYLAMINES AND THEIR APPLICATIONS |
-
2009
- 2009-11-30 EA EA201170741A patent/EA201170741A1/en unknown
- 2009-11-30 UY UY0001032276A patent/UY32276A/en not_active Application Discontinuation
- 2009-11-30 TW TW098140731A patent/TW201031407A/en unknown
- 2009-11-30 CA CA2745420A patent/CA2745420A1/en not_active Abandoned
- 2009-11-30 US US12/627,283 patent/US8133908B2/en not_active Expired - Fee Related
- 2009-11-30 MX MX2011005799A patent/MX2011005799A/en not_active Application Discontinuation
- 2009-11-30 EP EP09760530A patent/EP2370427A1/en not_active Withdrawn
- 2009-11-30 KR KR1020117015255A patent/KR20110091581A/en not_active Application Discontinuation
- 2009-11-30 CN CN2009801559246A patent/CN102300858A/en active Pending
- 2009-11-30 AU AU2009324238A patent/AU2009324238A1/en not_active Abandoned
- 2009-11-30 WO PCT/EP2009/066016 patent/WO2010063662A1/en active Application Filing
- 2009-11-30 AR ARP090104605A patent/AR074426A1/en not_active Application Discontinuation
- 2009-11-30 BR BRPI0922353A patent/BRPI0922353A2/en not_active IP Right Cessation
- 2009-11-30 JP JP2011538975A patent/JP2012510493A/en not_active Withdrawn
-
2011
- 2011-05-12 ZA ZA2011/03482A patent/ZA201103482B/en unknown
- 2011-05-16 IL IL212925A patent/IL212925A0/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002090355A1 (en) * | 2001-05-05 | 2002-11-14 | Smithkline Beecham P.L.C. | N-aroyl cyclic amines |
WO2004026866A1 (en) * | 2002-09-18 | 2004-04-01 | Glaxo Group Limited | N-aroyl cyclic amines as orexin receptor antagonists |
WO2004041816A1 (en) * | 2002-11-06 | 2004-05-21 | Glaxo Group Limited | Azacyclic compounds as orexin receptor antagonist |
WO2008038251A2 (en) * | 2006-09-29 | 2008-04-03 | Actelion Pharmaceuticals Ltd | 3-aza-bicyclo[3.1.0]hexane derivatives |
Cited By (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011023585A1 (en) * | 2009-08-24 | 2011-03-03 | Glaxo Group Limited | Piperidine derivatives used as orexin antagonists |
WO2011050198A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Disubstituted octahy - dropyrrolo [3,4-c] pyrroles as orexin receptor modulators |
US11667644B2 (en) | 2009-10-23 | 2023-06-06 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators |
US8680275B2 (en) | 2009-10-23 | 2014-03-25 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
US8653263B2 (en) | 2009-10-23 | 2014-02-18 | Janssen Pharmaceutica | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators |
US11059828B2 (en) | 2009-10-23 | 2021-07-13 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators |
WO2011050202A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
US9079911B2 (en) | 2009-10-23 | 2015-07-14 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators |
US9062044B2 (en) | 2009-10-23 | 2015-06-23 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators |
EP3093291A1 (en) | 2009-10-23 | 2016-11-16 | Janssen Pharmaceutica N.V. | Disubstituted octahy - dropyrrolo [3,4-c]pyrroles as orexin receptor modulators |
EP3581575A1 (en) | 2009-10-23 | 2019-12-18 | Janssen Pharmaceutica NV | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators |
WO2011050200A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
USRE48841E1 (en) | 2009-10-23 | 2021-12-07 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators |
WO2012085857A1 (en) | 2010-12-22 | 2012-06-28 | Actelion Pharmaceuticals Ltd | 3,8-diaza-bicyclo[4.2.0]oct-3-yl amides |
WO2012085852A1 (en) | 2010-12-22 | 2012-06-28 | Actelion Pharmaceuticals Ltd | 3,8-diaza-bicyclo[4.2.0]oct-8-yl amides |
WO2012089607A1 (en) * | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors |
WO2012089606A1 (en) * | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists |
US9586962B2 (en) | 2011-04-20 | 2017-03-07 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators |
WO2012145581A1 (en) | 2011-04-20 | 2012-10-26 | Janssen Pharmaceutica Nv | Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators |
WO2013050938A1 (en) | 2011-10-04 | 2013-04-11 | Actelion Pharmaceuticals Ltd | 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives |
WO2013068935A1 (en) | 2011-11-08 | 2013-05-16 | Actelion Pharmaceuticals Ltd | 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists |
US9150566B2 (en) | 2011-11-08 | 2015-10-06 | Actelion Pharmaceuticals Ltd. | 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-YL)picolinamide derivatives as orexin receptor antagonists |
US9896452B2 (en) | 2012-02-07 | 2018-02-20 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
US9499517B2 (en) | 2012-02-07 | 2016-11-22 | Eolas Therapeutics, Inc. | Substituted prolines / piperidines as orexin receptor antagonists |
US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
US9416109B2 (en) | 2012-02-17 | 2016-08-16 | Eisai R&D Management Co., Ltd. | Methods and compounds useful in the synthesis of orexin-2 receptor antagonists |
US9828336B2 (en) | 2012-02-17 | 2017-11-28 | Eisai R&D Management Co., Ltd. | Methods and compounds useful in the synthesis of orexin-2 receptor antagonists |
JP2015510909A (en) * | 2012-03-19 | 2015-04-13 | ロッタファーム・バイオテック・ソチエタ・ア・レスポンサビリタ・リミタータROTTAPHARM BIOTECH S.r.l. | Compound |
US9174977B2 (en) | 2012-03-19 | 2015-11-03 | Rottapharm Biotech S.R.L. | 2-azabicyclo[4.1.0]heptane derivatives as orexin receptor antagonists for the treatment of certain disorders |
WO2013139730A1 (en) * | 2012-03-19 | 2013-09-26 | Rottapharm Spa | Chemical compounds |
ITMI20120424A1 (en) * | 2012-03-19 | 2013-09-20 | Rottapharm Spa | CHEMICAL COMPOUNDS |
US10329287B2 (en) | 2012-06-04 | 2019-06-25 | Idorsia Pharmaceuticals Ltd | Benzimidazole-proline derivatives |
US9732075B2 (en) | 2012-06-04 | 2017-08-15 | Idorsia Pharmaceuticals Ltd | Benzimidazole-proline derivatives |
US11040966B2 (en) | 2012-06-04 | 2021-06-22 | Idorsia Pharmaceuticals Ltd | Benzimidazole-proline derivatives |
WO2013182972A1 (en) | 2012-06-04 | 2013-12-12 | Actelion Pharmaceuticals Ltd | Benzimidazole-proline derivatives |
US9493446B2 (en) | 2012-10-10 | 2016-11-15 | Actelion Pharmaceuticals Ltd. | Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives |
WO2014057435A1 (en) | 2012-10-10 | 2014-04-17 | Actelion Pharmaceuticals Ltd | Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives |
WO2014141065A1 (en) | 2013-03-12 | 2014-09-18 | Actelion Pharmaceuticals Ltd | Azetidine amide derivatives as orexin receptor antagonists |
US9403813B2 (en) | 2013-03-12 | 2016-08-02 | Actelion Pharmaceuticals Ltd. | Azetidine amide derivatives as orexin receptor antagonists |
WO2015083070A1 (en) | 2013-12-03 | 2015-06-11 | Actelion Pharmaceuticals Ltd | Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists |
US10023560B2 (en) | 2013-12-03 | 2018-07-17 | Idorsia Pharmaceuticals Ltd | Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
US9914720B2 (en) | 2013-12-03 | 2018-03-13 | Idorsia Pharmaceuticals Ltd | Crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[D]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists |
US9790208B2 (en) | 2013-12-03 | 2017-10-17 | Idorsia Pharmaceuticals Ltd | Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
WO2015083071A1 (en) | 2013-12-03 | 2015-06-11 | Actelion Pharmaceuticals Ltd | Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1 h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
US9914721B2 (en) | 2013-12-04 | 2018-03-13 | Idorsia Pharmaceuticals Ltd | Use of benzimidazole-proline derivatives |
WO2015083094A1 (en) | 2013-12-04 | 2015-06-11 | Actelion Pharmaceuticals Ltd | Use of benzimidazole-proline derivatives |
US10221170B2 (en) | 2014-08-13 | 2019-03-05 | Eolas Therapeutics, Inc. | Difluoropyrrolidines as orexin receptor modulators |
US10894789B2 (en) | 2016-02-12 | 2021-01-19 | Astrazeneca Ab | Halo-substituted piperidines as orexin receptor modulators |
US11434236B2 (en) | 2016-02-12 | 2022-09-06 | Astrazeneca Ab | Halo-substituted piperidines as orexin receptor modulators |
US11241432B2 (en) | 2016-03-10 | 2022-02-08 | Janssen Pharmaceutica Nv | Methods of treating depression using orexin-2 receptor antagonists |
US10828302B2 (en) | 2016-03-10 | 2020-11-10 | Janssen Pharmaceutica Nv | Methods of treating depression using orexin-2 receptor antagonists |
WO2018146466A1 (en) | 2017-02-09 | 2018-08-16 | Benevolentai Bio Limited | Orexin receptor antagonists |
WO2018206956A1 (en) | 2017-05-10 | 2018-11-15 | Benevolentai Bio Limited | Orexin receptor antagonists |
WO2018206959A1 (en) | 2017-05-10 | 2018-11-15 | Benevolentai Bio Limited | Orexin receptor antagonists |
WO2020007964A1 (en) | 2018-07-05 | 2020-01-09 | Idorsia Pharmaceuticals Ltd | 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives |
WO2020099511A1 (en) | 2018-11-14 | 2020-05-22 | Idorsia Pharmaceuticals Ltd | Benzimidazole-2-methyl-morpholine derivatives |
WO2023218023A1 (en) | 2022-05-13 | 2023-11-16 | Idorsia Pharmaceuticals Ltd | Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives |
Also Published As
Publication number | Publication date |
---|---|
KR20110091581A (en) | 2011-08-11 |
MX2011005799A (en) | 2011-06-20 |
TW201031407A (en) | 2010-09-01 |
CA2745420A1 (en) | 2010-06-10 |
ZA201103482B (en) | 2012-01-25 |
UY32276A (en) | 2010-05-31 |
EP2370427A1 (en) | 2011-10-05 |
US8133908B2 (en) | 2012-03-13 |
EA201170741A1 (en) | 2011-12-30 |
AU2009324238A1 (en) | 2010-06-10 |
IL212925A0 (en) | 2011-07-31 |
CN102300858A (en) | 2011-12-28 |
AR074426A1 (en) | 2011-01-19 |
JP2012510493A (en) | 2012-05-10 |
US20100168131A1 (en) | 2010-07-01 |
BRPI0922353A2 (en) | 2018-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8133908B2 (en) | Heteroaryl derivatives of N-{[(1S,4S,6S)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-amine | |
US20120040991A1 (en) | 3-azabicyclo [4.1.0] heptanes used as orexin antagonists | |
US20110257198A1 (en) | Piperidine derivatives useful as orexin antagonists | |
US20110053979A1 (en) | Pyridine derivatives used to treat orexin related disorders | |
WO2012089606A1 (en) | Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists | |
US20100144760A1 (en) | Novel compounds | |
WO2009003997A1 (en) | Imidazo [1, 2-c] pyrimidin-2-ylmethylpiperidines as orexin receptor antagonists | |
EP2470523A1 (en) | 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder | |
WO2010060470A1 (en) | Piperidine derivatives useful as orexin receptor antagonists | |
EP2358712A1 (en) | Piperidine derivatives useful as orexin receptor antagonists | |
WO2012089607A1 (en) | Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors | |
WO2011023585A1 (en) | Piperidine derivatives used as orexin antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980155924.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09760530 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 212925 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009324238 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2745420 Country of ref document: CA Ref document number: 2011538975 Country of ref document: JP Ref document number: MX/A/2011/005799 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009760530 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2009324238 Country of ref document: AU Date of ref document: 20091130 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4774/DELNP/2011 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 20117015255 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201170741 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: PI0922353 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110601 |